|
FDA Panel Backs Benefit Of Experimental Drug For Rare Lung Disease
An FDA panel Tuesday narrowly voted in favor of the benefits of an experimental drug for the treatment of a rare lung disease.
|
|
0 Comments
Font Size:
WASHINGTON (March 9, 2010)--Federal health advisers said Tuesday an experimental drug from InterMune Inc. provides a meaningful benefit for patients with a rare lung disease.
The Food and Drug Administration's panel of lung experts narrowly voted 7-5 in favor of the benefits of the company's drug pirfenidone.
The FDA is not required to follow the group's advice, although it often does.
The panel is scheduled to vote later in the day on the drug's safety.
InterMune is asking the Food and Drug Administration to approve its drug for idiopathic pulmonary fibrosis, an often-fatal lung disease for which there are no approved drugs.
More Stories
KWTX.com Features
 |
Double
Dollar Deals Half Price Deals at Central Texas restaurants and businesses. A new deal every Thursday at 7:00am. |
 |
Law
Line This free service can help you find answers to your legal questions about personal injury, criminal law, bankruptcy, family law and more. |
 |
Army Way Learn all about the symbols, traditions, and customs of the US Army. |
For Your Health
